What is Merck's proposed use of molnupiravir in the current Ebola outbreak, and why is it being considered?

Merck is discussing making its COVID-19 antiviral pill molnupiravir available as a potential treatment for the ongoing Ebola outbreak in the Democratic Republic of the Congo, which involves the rare Bundibugyo strain—a virus for which there are no approved vaccines or treatments. Eliav Barr, Merck’s chief medical officer, stated that molnupiravir is 'a non-specific RNA virus drug' and that the company is exploring how it could be used against Ebola; this consideration is supported by prior animal studies showing some efficacy against Ebola, though it is not an approved Ebola treatment. The drug is also being evaluated for potential use in preventing infection among high-risk individuals, with the caveat that it is not recommended during pregnancy.

How does Merck’s existing Ebola vaccine Ervebo relate to the current outbreak, and what is the company’s stance on adapting it?

Merck’s approved Ebola vaccine Ervebo is designed specifically for the Zaire strain of Ebola—not the Bundibugyo strain causing the current outbreak—so it is not directly applicable. However, Barr noted that the underlying technology of Ervebo 'may be useful in developing a new vaccine' and that scientists 'may be able to alter it,' indicating exploratory efforts to adapt the platform for Bundibugyo. He confirmed Merck is actively assessing this possibility as part of its broader response to the outbreak.

Merck Discusses Using COVID Antiviral Drug for Ebola Response

Jun 1, 2026

Merck executives are exploring molnupiravir as an Ebola treatment amid a worsening outbreak in the DRC. The company also noted potential applications for its existing Ebola vaccine technology against the rare Bundibugyo strain.

reuters

2026-06-01

Merck Discusses Using COVID Antiviral Drug for Ebola Response

2026-06-11

US Screwworm Cases Test Months of Federal Preparation

2026-08-20

Ebola Vaccine Enters Phase 3 Trial. Will It Work on a New Target?

Merck Discusses Using COVID Antiviral Drug for Ebola Response

FAQ